Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
Margaret Shipp, Wellesley, MA (US); Jing Ouyang, Chestnut Hill, MA (US); Kunihiko Takeyama, Tokyo (JP); Jeffery L. Kutok, Natick, MA (US); Scott J. Rodig, Westwood, MA (US); Gabriel Rabinovich, Ciudad de Buenos Aires (AR); Diego Omar Croci Russo, Provincia de Buenos Aires (AR); and Mariana Salatino, Buenos Aires (AR)
Assigned to Dana-Farber Cancer Institute, Inc., Boston, MA (US); The Brigham and Women's Hospital, Inc., Boston, MA (US); Consejo Nacional De Investigaciones Científicas y Técnicas (CONICET), Ciudad de Buenos Aires (AR); and Fundacion Sales, Ciudad Autonoma de Buenos Aires (AR)
Filed by Dana-Farber Cancer Institute, Inc., Boston, MA (US); The Brigham and Women's Hospital, Inc., Boston, MA (US); Consejo Nacional de Investigaciones Cientificas y Técnicas (CONICET), Ciudad de Buenos Aires (AR); and Fundacion Sales, Ciudad Autonoma de Buenos Aires (AR)
Filed on Sep. 17, 2019, as Appl. No. 16/573,374.
Application 16/573,374 is a division of application No. 14/598,405, filed on Jan. 16, 2015, granted, now 10,456,465.
Application 14/598,405 is a continuation of application No. 13/509,466, granted, now 8,968,740, previously published as PCT/US2010/056547, filed on Nov. 12, 2010.
Claims priority of provisional application 61/335,779, filed on Jan. 12, 2010.
Claims priority of provisional application 61/283,159, filed on Nov. 30, 2009.
Claims priority of provisional application 61/261,125, filed on Nov. 13, 2009.
Prior Publication US 2020/0093920 A1, Mar. 26, 2020
1. A method of detecting the presence or level of a human galectin 1 (Gal1) polypeptide said method comprising obtaining a sample comprising protein from a human subject and detecting said polypeptide in the sample by use of at least one monoclonal antibody, or antigen-binding fragment thereof, that specifically binds Gal1 and comprises six CDRs: CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, wherein CDR-H1 consists of residues 31-35 of SEQ ID NO: 7, CDR-H2 consists of residues 50-66 of SEQ ID NO: 7, CDR-H3 consists of residues 99-107 of SEQ ID NO: 7, CDR-L1 consists of residues 23-36 of SEQ ID NO: 9, CDR-L2 consists of residues 52-58 of SEQ ID NO: 9, and CDR-L3 consists of residues 91-99 of SEQ ID NO: 9.